Tirzepatide
aka Tirzepatide (GIP/GLP-1 dual receptor agonist — Mounjaro, Zepbound)
Mechanism
Tirzepatide is a unimolecular dual GIP and GLP-1 receptor agonist with a half-life of approximately 5 days, enabling once-weekly subcutaneous dosing. It is FDA-approved as Mounjaro for type 2 diabetes (2022), Zepbound for chronic weight management in adults with obesity or overweight with a weight-related comorbidity (2023), and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). It carries a BOXED WARNING for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Identification
Vendors selling Tirzepatide
No vendor listings on file yet.
Research
No citations on file yet.